Dendrite Provides Third Quarter Earnings Update.

Business Editors

MORRISTOWN, NJ--(BUSINESS WIRE)--Sept. 20, 2001

Dendrite (NASDAQ/NMS: DRTE) today confirmed that it expects third quarter earnings to meet or exceed previous guidance of $.08 per share, including all investment in CRM but excluding restructuring and non-recurring charges. The company indicated that its proposal activity appeared to be accelerating and that both prospects and existing customers were beginning to make decisions.

"We are pleased that our pace of business appears to be picking up and that our cost-containment actions will give us solid profitability for the quarter," commented John Bailye, Chairman and CEO of Dendrite. "Looking ahead, fourth-quarter visibility is good and we are maintaining our previous guidance."

The company indicated that it remained cautious on 2002, given the current global economic weakness and the uncertainty resulting from the terrorist attacks on Washington, DC and New York City. Consequently, it plans to continue to tightly control costs until solid revenue growth materializes.

"In the past, we have demonstrated that we can staff quickly to meet unanticipated demand, and we will position ourselves to be able to do it again," Bailye added; "however, we will not let our resource levels get ahead of revenue as we did in the first half of 2001."

The company indicated that it would release earnings and host a conference call after the market closes on Tuesday, October 23.

About Dendrite

Dendrite, the visionary innovator in global pharmaceutical technology, helps clients strategically manage their customer relationships to increase market share. The company creates unique, analytically driven solutions that enable pharmaceutical companies to influence prescriber behavior, thereby delivering a sustained competitive advantage. More than 80,000 pharmaceutical sales representatives and their managers from over 150 companies and 57 countries use Dendrite products and services. They represent 19 of the top 20 pharmaceutical companies. For more information, visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc. The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan," and similar statements or variations. Such forward-looking statements are based on our current estimates and assumptions and involve certain significant risks and uncertainties, including: risks associated with and dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy selling cycles, product implementation cycles, customer budget cycles, and timing of revenue recognition; dependence on major customers; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; retention of key senior managers; and unique characteristics of the consumer packaged goods industry. Other important factors that should be considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements.